Advancing a new generation of treatments for
central nervous system disorders
Latest News
2 Oct 2014
NeurOp Receives Milestone Payment as Bristol-Myers Squibb Nominates NMDA Recepto ...
Read More
29 Sep 2014
NeurOp Awarded NIH Grant for Alzheimer’s Disease Drug Research
Read More
11 Aug 2014
Lee H. Latimer Joins NeurOp to Manage Its Chemistry Operations
Read More
NeurOp, Inc. is a biopharmaceutical company developing new medicines to treat central nervous system disorders,
including major depression, neuropathic pain and ischemia. Our mission is to develop a new generation of
N-methyl-D-aspartate (NMDA) receptor blockers, which inhibit proteins that play an important role in neuron signaling.
Our compounds specifically target the NR2B subtype of these receptors offering an unprecedented
opportunity to improve the safety and tolerability of this therapeutic class without compromising efficacy.
Learn more about our science.